All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

mequitazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	1707	29216-28-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mequitazine metaplexan nipolazin	Molecular weight: 322.47 Formula: C20H22N2S CLOGP: 4.91 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 6.48 ALOGS: -4.91 ROTB: 2

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Property	Value	Reference
fu (Fraction unbound in plasma)	0.04 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK12,MAPK7,MET,NTRK2,PDK2,PDK4,PDPK1,PIM2,PRKDC,TEK,TTK	30
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tubulointerstitial nephritis and uveitis syndrome	54.54	42.05	6	80	266	90628095

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tubulointerstitial nephritis and uveitis syndrome	46.32	39.42	6	264	400	110588629

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R06AD07	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Phenothiazine derivatives
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018494	Histamine Agents

Related Drugs by ATC class:

R06AD Phenothiazine derivatives 8 drugs

alimemazinehydroxyethylpromethazineisothipendylmethdilazineoxomemazinepromethazinethiazinamthiethylperazine

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.22	Basic
pKa2	3.55	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.24		PDSP
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	8.25		PDSP
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.85		PDSP
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	8.28		PDSP
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.96		PDSP
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.96		PDSP
Trypanothione reductase	Enzyme		TYTR_TRYCR		IC50	4.66		CHEMBL
Histamine H1 receptor	GPCR		HRH1_CAVPO		Ki	8		CHEMBL
Trypanothione reductase	Enzyme		Q389T8_TRYB2		IC50	4.27		CHEMBL

External reference:

ID	Source
D01324	KEGG_DRUG
C0065972	UMLSCUI
CHEBI:31821	CHEBI
CHEMBL73451	ChEMBL_ID
DB01071	DRUGBANK_ID
C006069	MESH_SUPPLEMENTAL_RECORD_UI
4066	PUBCHEM_CID
3672	INN_ID
Y463242LY2	UNII
29528	RXNORM
004003	NDDF
320756004	SNOMEDCT_US
414674005	SNOMEDCT_US

Pharmaceutical products:

None